Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome

Amy H. Farabaugh, Stella Bitran, Janet Witte, Jonathan E. Alpert, Sarah Chuzi, Alisabet J. Clain, Lee Baer, Maurizio Fava, Patrick J. McGrath, Christina Dording, David Mischoulon, George I. Papakostas

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine. We also examined the relationship between anxious depression and treatment response. Five hundred and ten major depressive disorder patients received 12 weeks of fluoxetine with flexible dosing [target dosages: 10 mg/day (week 1), 20 mg/day (weeks 2-4), 40 mg/day (weeks 4-8), and 60 mg/day (weeks 5-12)]. We assessed the relationship between early changes in 17-item Hamilton Rating Scale for Depression (HAMD-17)-anxiety/somatization factor items and depressive remission, as well as whether anxious depression at baseline predicted remission at study endpoint. Baseline HAMD-17 scores were considered as covariates and the Bonferroni correction (P≤0.008) was used for multiple comparisons. Adjusting for baseline HAMD-17 scores, patients who experienced greater early improvement in somatic symptoms (gastrointestinal) were significantly more likely to attain remission (HAMD-17 <8) at endpoint than those without early improvement (P=0.006). Early changes in the remaining items did not predict remission, nor did anxious depression at baseline. In conclusion, among the anxiety/somatization factor items, only early changes in somatic symptoms (gastrointestinal) predicted remission. Future studies are warranted to further investigate this relationship as well as that between anxious depression and treatment outcome.

Original languageEnglish (US)
Pages (from-to)214-217
Number of pages4
JournalInternational Clinical Psychopharmacology
Volume25
Issue number4
DOIs
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Antidepressive Agents
Anxiety
Depression
Fluoxetine
Major Depressive Disorder
Medically Unexplained Symptoms
Therapeutics

Keywords

  • Antidepressants
  • Anxiety
  • Anxious depression
  • Depression
  • Predictors
  • Remission

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. / Farabaugh, Amy H.; Bitran, Stella; Witte, Janet; Alpert, Jonathan E.; Chuzi, Sarah; Clain, Alisabet J.; Baer, Lee; Fava, Maurizio; McGrath, Patrick J.; Dording, Christina; Mischoulon, David; Papakostas, George I.

In: International Clinical Psychopharmacology, Vol. 25, No. 4, 07.2010, p. 214-217.

Research output: Contribution to journalArticle

Farabaugh, AH, Bitran, S, Witte, J, Alpert, JE, Chuzi, S, Clain, AJ, Baer, L, Fava, M, McGrath, PJ, Dording, C, Mischoulon, D & Papakostas, GI 2010, 'Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome', International Clinical Psychopharmacology, vol. 25, no. 4, pp. 214-217. https://doi.org/10.1097/YIC.0b013e328339fbbd
Farabaugh, Amy H. ; Bitran, Stella ; Witte, Janet ; Alpert, Jonathan E. ; Chuzi, Sarah ; Clain, Alisabet J. ; Baer, Lee ; Fava, Maurizio ; McGrath, Patrick J. ; Dording, Christina ; Mischoulon, David ; Papakostas, George I. / Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. In: International Clinical Psychopharmacology. 2010 ; Vol. 25, No. 4. pp. 214-217.
@article{1a55339be810414086aed8b36ae70bb7,
title = "Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome",
abstract = "The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine. We also examined the relationship between anxious depression and treatment response. Five hundred and ten major depressive disorder patients received 12 weeks of fluoxetine with flexible dosing [target dosages: 10 mg/day (week 1), 20 mg/day (weeks 2-4), 40 mg/day (weeks 4-8), and 60 mg/day (weeks 5-12)]. We assessed the relationship between early changes in 17-item Hamilton Rating Scale for Depression (HAMD-17)-anxiety/somatization factor items and depressive remission, as well as whether anxious depression at baseline predicted remission at study endpoint. Baseline HAMD-17 scores were considered as covariates and the Bonferroni correction (P≤0.008) was used for multiple comparisons. Adjusting for baseline HAMD-17 scores, patients who experienced greater early improvement in somatic symptoms (gastrointestinal) were significantly more likely to attain remission (HAMD-17 <8) at endpoint than those without early improvement (P=0.006). Early changes in the remaining items did not predict remission, nor did anxious depression at baseline. In conclusion, among the anxiety/somatization factor items, only early changes in somatic symptoms (gastrointestinal) predicted remission. Future studies are warranted to further investigate this relationship as well as that between anxious depression and treatment outcome.",
keywords = "Antidepressants, Anxiety, Anxious depression, Depression, Predictors, Remission",
author = "Farabaugh, {Amy H.} and Stella Bitran and Janet Witte and Alpert, {Jonathan E.} and Sarah Chuzi and Clain, {Alisabet J.} and Lee Baer and Maurizio Fava and McGrath, {Patrick J.} and Christina Dording and David Mischoulon and Papakostas, {George I.}",
year = "2010",
month = "7",
doi = "10.1097/YIC.0b013e328339fbbd",
language = "English (US)",
volume = "25",
pages = "214--217",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome

AU - Farabaugh, Amy H.

AU - Bitran, Stella

AU - Witte, Janet

AU - Alpert, Jonathan E.

AU - Chuzi, Sarah

AU - Clain, Alisabet J.

AU - Baer, Lee

AU - Fava, Maurizio

AU - McGrath, Patrick J.

AU - Dording, Christina

AU - Mischoulon, David

AU - Papakostas, George I.

PY - 2010/7

Y1 - 2010/7

N2 - The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine. We also examined the relationship between anxious depression and treatment response. Five hundred and ten major depressive disorder patients received 12 weeks of fluoxetine with flexible dosing [target dosages: 10 mg/day (week 1), 20 mg/day (weeks 2-4), 40 mg/day (weeks 4-8), and 60 mg/day (weeks 5-12)]. We assessed the relationship between early changes in 17-item Hamilton Rating Scale for Depression (HAMD-17)-anxiety/somatization factor items and depressive remission, as well as whether anxious depression at baseline predicted remission at study endpoint. Baseline HAMD-17 scores were considered as covariates and the Bonferroni correction (P≤0.008) was used for multiple comparisons. Adjusting for baseline HAMD-17 scores, patients who experienced greater early improvement in somatic symptoms (gastrointestinal) were significantly more likely to attain remission (HAMD-17 <8) at endpoint than those without early improvement (P=0.006). Early changes in the remaining items did not predict remission, nor did anxious depression at baseline. In conclusion, among the anxiety/somatization factor items, only early changes in somatic symptoms (gastrointestinal) predicted remission. Future studies are warranted to further investigate this relationship as well as that between anxious depression and treatment outcome.

AB - The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine. We also examined the relationship between anxious depression and treatment response. Five hundred and ten major depressive disorder patients received 12 weeks of fluoxetine with flexible dosing [target dosages: 10 mg/day (week 1), 20 mg/day (weeks 2-4), 40 mg/day (weeks 4-8), and 60 mg/day (weeks 5-12)]. We assessed the relationship between early changes in 17-item Hamilton Rating Scale for Depression (HAMD-17)-anxiety/somatization factor items and depressive remission, as well as whether anxious depression at baseline predicted remission at study endpoint. Baseline HAMD-17 scores were considered as covariates and the Bonferroni correction (P≤0.008) was used for multiple comparisons. Adjusting for baseline HAMD-17 scores, patients who experienced greater early improvement in somatic symptoms (gastrointestinal) were significantly more likely to attain remission (HAMD-17 <8) at endpoint than those without early improvement (P=0.006). Early changes in the remaining items did not predict remission, nor did anxious depression at baseline. In conclusion, among the anxiety/somatization factor items, only early changes in somatic symptoms (gastrointestinal) predicted remission. Future studies are warranted to further investigate this relationship as well as that between anxious depression and treatment outcome.

KW - Antidepressants

KW - Anxiety

KW - Anxious depression

KW - Depression

KW - Predictors

KW - Remission

UR - http://www.scopus.com/inward/record.url?scp=77953723909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953723909&partnerID=8YFLogxK

U2 - 10.1097/YIC.0b013e328339fbbd

DO - 10.1097/YIC.0b013e328339fbbd

M3 - Article

C2 - 20400905

AN - SCOPUS:77953723909

VL - 25

SP - 214

EP - 217

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 4

ER -